What are the indications, dosing regimens, administration guidelines, and contraindications for human serum albumin (20% solution) as a volume‑expanding colloid?

Human Serum Albumin 20% Solution: Clinical Use Guidelines

Primary Recommendation

Human serum albumin 20% solution should be reserved primarily for cirrhosis-related complications (large-volume paracentesis, spontaneous bacterial peritonitis, hepatorenal syndrome) and as a second-line volume expander in specific shock states when crystalloids are insufficient—routine use for hypoalbuminemia correction, nutritional support, or most critical care scenarios is not recommended. 1, 2

---

Evidence-Based Indications

Strong Recommendations (High-Quality Evidence)

Cirrhosis with Large-Volume Paracentesis:

• Albumin is conditionally recommended for patients undergoing large-volume paracentesis to prevent post-paracentesis circulatory dysfunction 1
• Dosing: 6-8 g of albumin per liter of ascitic fluid removed 3

Spontaneous Bacterial Peritonitis (SBP) in Cirrhosis:

• Albumin is conditionally recommended in combination with antibiotics 1
• Dosing: 1.5 g/kg at diagnosis, followed by 1 g/kg on day 3 3

Hepatorenal Syndrome (HRS-AKI):

• Albumin is the volume expander of choice for hospitalized cirrhosis patients with ascites presenting with acute kidney injury 1
• Dosing: 1 g/kg daily for 2 consecutive days (maximum 100 g/day) 1
• Must be combined with vasoconstrictors (terlipressin, norepinephrine, or octreotide/midodrine combination) specifically for HRS-AKI, not other forms of AKI 1

Conditional/Second-Line Indications (Moderate-Quality Evidence)

Fluid Resuscitation in Shock States:

• Use as second-line therapy adjunctive to crystalloids in hypovolemic shock, septic shock, and severe burns when crystalloids alone are insufficient 3
• The 2024 International Collaboration for Transfusion Medicine Guidelines explicitly recommend against routine albumin use in critical care patients 1
• Dosing for volume expansion: The oncotic pressure of 20% albumin is approximately four times higher than normal serum; it expands plasma volume by drawing interstitial water 2
• Should be combined with isotonic electrolyte solutions at an albumin:electrolyte ratio of 1:3 or 1:4 for acute volume deficits 2

Post-Cardiac Surgery:

• Recent 2024 multicenter RCT showed 20% albumin fluid bolus therapy reduced positive fluid balance by approximately 700 mL but did not significantly reduce vasopressor duration (median difference -3.8 hours, P=0.08) 4
• Earlier 2019 pilot study suggested benefits including less positive fluid balance and shorter norepinephrine duration, but the larger definitive trial was equivocal 5, 4
• Consider as adjunctive therapy when crystalloid-based fluid bolus therapy results in excessive positive fluid balance 4

Plasmapheresis:

• Moderate-quality evidence supports albumin for fluid replacement during plasmapheresis procedures 3

---

Administration Guidelines

Dosing Regimens by Indication:

• Volume deficit (acute): Combine with crystalloids at 1:3 or 1:4 ratio; 20% albumin draws approximately 3-4 times its volume from interstitial space 2
• Volume deficit (chronic): Trial with 20% albumin alone may be appropriate when tissue edema suggests compensatory sodium/water retention 2
• Oncotic deficit threshold: Target serum total protein >5.2 g/dL (equivalent to oncotic pressure ~20 mmHg) to reduce complication risk 2
• Long-term cirrhosis management: Ongoing trial evaluating 1.5 g/kg every 10 days for up to 12 months in decompensated cirrhosis with ascites 1

Administration Considerations:

• Manifest hypoproteinemia typically indicates an extravascular albumin deficit of equal magnitude to the intravascular deficit 2
• Infusion rate should account for capillary permeability and risk of volume overload 2
• Monitor for pulmonary edema, particularly in patients with cardiovascular or renal dysfunction 6

---

Contraindications and Safety

Absolute Contraindication:

• History of incompatibility reaction to human albumin in the individual recipient 2

Critical Safety Warnings:

Heart Failure with Hypoalbuminemia:

• A 2025 propensity-matched analysis found albumin infusion in heart failure patients with serum albumin ≤2.9 g/dL was associated with significantly higher in-hospital mortality (p<0.001) and prolonged ICU/hospital stays 7
• Exercise extreme caution or avoid albumin administration in heart failure patients with low serum albumin 7

Risk of Volume Overload:

• Routine fixed-dose albumin in AKI may cause volume overload and pulmonary edema 1
• Volume replacement should ideally be tailored to patient volume status, though optimal assessment methods remain unclear 1

Renal Dysfunction:

• Patients developing renal dysfunction as their only organ dysfunction have poor prognosis; only 1 of 3 survived at 30 days in one feasibility study 6
• Contrast with cardiovascular/respiratory dysfunction where 12 of 13 patients survived 6

---

Explicitly NOT Recommended Uses

The following indications lack evidence and should be avoided: 1, 8

• Routine correction of hypoalbuminemia without hypovolemia
• Nutritional intervention or protein supplementation
• Neonatal, pediatric, or adult critical care patients (routine use)
• Intradialytic hypotension
• Cardiovascular surgery (routine prophylactic use)
• Treatment of extraperitoneal infections in cirrhosis
• Correction of hypoalbuminemia in hospitalized cirrhosis patients without specific complications

---

Common Pitfalls

Misunderstanding Hypoalbuminemia:

• Low serum albumin alone is NOT an indication for albumin administration 1, 8
• Hypoalbuminemia reflects underlying disease processes (malnutrition, inflammation, hepatic dysfunction, renal losses) that require specific treatment 2, 8
• Albumin infusion for hypoalbuminemia per se remains a common inappropriate use despite lack of evidence 8

Inappropriate Critical Care Use:

• Despite ongoing large trials in septic shock, cardiac surgery, and acute kidney injury, current evidence does not support routine albumin use in these settings 1
• Wait for completion of ongoing RCTs before expanding indications 1

Failure to Combine with Appropriate Therapies:

• In HRS-AKI, albumin alone is insufficient—must combine with vasoconstrictors 1
• In acute volume deficit, albumin should be combined with crystalloids unless chronic compensated deficit 2

---

Quality of Evidence Summary

Strong evidence (moderate-high quality): Cirrhosis complications (large-volume paracentesis, SBP, HRS-AKI), plasmapheresis 1, 3

Weak evidence (low-moderate quality): Fluid resuscitation in refractory shock, severe burns, post-cardiac surgery fluid management 1, 3, 4

Insufficient evidence: Routine critical care use, intradialytic hypotension, cardiovascular surgery prophylaxis, hypoalbuminemia correction 1, 8

Contraindicated by safety data: Heart failure with hypoalbuminemia 7